The effect of Yu-Ping-Feng capsules and Fu-Fang-Dan-Shen tablets on stable COPD

M. Jie, M. Bing (Chengdu, China)

Source: Annual Congress 2013 –COPD biomarkers
Session: COPD biomarkers
Session type: Thematic Poster Session
Number: 2174
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Jie, M. Bing (Chengdu, China). The effect of Yu-Ping-Feng capsules and Fu-Fang-Dan-Shen tablets on stable COPD. Eur Respir J 2013; 42: Suppl. 57, 2174

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016

Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013



Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015

Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016

Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD
Source: Annual Congress 2013 –COPD treatment
Year: 2013


Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Once-daily QVA149 has a good safety profile in patients with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014

QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Effects of ciclesonide on the management of stable COPD with airway eosinophilia
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013


Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013


QVA149 provides superior peak lung function in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013